Product Information

GABAPENTIN 400 MG CAPSULE is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.0422 per EA under NDC 31722015005. Its NADAC has been published 152 times since Nov 8, 2023.

FDA first approved this application on May 10, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

GABAPENTIN 400 MG CAPSULE

gabapentin
$0.0422per EA
High Outlier

Strength

400 mg/1

NDC

31722015005

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

9/23/2026

Active Ingredients

GABAPENTIN

Approval Type

Generic (ANDA)

FDA Application

ANDA214956

FDA Approved

5/10/2021

TE Code

AB

On Market Since

5/10/2021

Pharmacological Classes

Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for GABAPENTIN 400 MG CAPSULE has been published 152 times since Nov 8, 2023, and over the history we have for it it has declined 22.4%. The table below summarizes its recorded NADAC range and movement.

Current price$0.0422 per EA
All-time high$0.0587 (Feb 14, 2024)
All-time low$0.0396 (Apr 22, 2026)
52-week high$0.0434
52-week low$0.0396
Median price$0.0445
Average price$0.0463
Largest weekly change+23.4% (Aug 21, 2024)
Weeks tracked152
Tracking sinceNov 8, 2023

Price History

1W

0.0%

1M

+5.6%

3M

+2.9%

6M

+6.1%

1Y

-2.7%

3Y

N/A

5Y

N/A

All

-22.4%

Generic Alternatives

The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of GABAPENTIN 400 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 400 MG CAPSULE, manufactured by Camber Pharmaceuticals Inc., is $0.0422 per EA (NDC 31722015005), effective Sep 30, 2026.

How has the price of GABAPENTIN 400 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for GABAPENTIN 400 MG CAPSULE has declined 22.4%. It has been tracked across 152 weekly CMS publications since Nov 8, 2023.

What are the highest and lowest recorded NADAC prices for GABAPENTIN 400 MG CAPSULE?

Since Nov 8, 2023, the NADAC for GABAPENTIN 400 MG CAPSULE has ranged from a low of $0.0396 (Apr 22, 2026) to a high of $0.0587 (Feb 14, 2024), with a median of $0.0445 per EA.

Are there cheaper alternatives to GABAPENTIN 400 MG CAPSULE?

Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN 400 MG CAPSULE, is $0.0400 per EA — about 5% below GABAPENTIN 400 MG CAPSULE.

Who manufactures GABAPENTIN 400 MG CAPSULE?

GABAPENTIN 400 MG CAPSULE (NDC 31722015005) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.